Guideline of selective parathyroid percutaneous etanol injection therapy for patients with advanced renal hyperparathyroidism

Tominaga, Yoshihiro; 正史, 貴田岡; 雅史, 深川; 忠男, 秋澤; 清, 黒川

doi:10.4009/jsdt.32.1099

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This post-PEIT management is the key to maintaining optimal parathyroid function [ 14 ]. After carefully assessing all aspects of PEIT, we established the first practical Japanese guidelines for PEIT in 2000 [ 15 ] by modifying tentative guidelines that were published in 1999 [ 16 ]. These guidelines published in 2000 have been widely used to guide bedside practice.…”

Section: Introductionmentioning

confidence: 99%

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients

Onoda¹,

Fukagawa²,

Tominaga³

et al. 2008

Clinical Kidney Journal

View full text Add to dashboard Cite

In 2000, the Japanese Society for Parathyroid Intervention issued the ‘Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients’. Since then, the concept of ‘selective PEIT’ has been well accepted and the number of patients treated by this method in Japan has increased. Recently, it has been reported that the effect of PEIT differs depending on the degree of nodular hyperplasia. Several new drugs have become available since 2000, and active vitamin D and its analogue have also been used for direct injection into the parathyroids. We present the new ‘Guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients’, a revised version of the 2000 Guidelines. We believe that these new guidelines are useful for selecting direct injection therapy in patients with advanced secondary hyperparathyroidism.

show abstract

Section: Introductionmentioning

confidence: 99%

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients

Onoda¹,

Fukagawa²,

Tominaga³

et al. 2008

Clinical Kidney Journal

View full text Add to dashboard Cite

show abstract

Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan

Iseki

2008

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Secondary hyperparathyroidism has a significant impact on morbidity and mortality due to skeletal and extraskeletal manifestations. Cinacalcet, a newly developed calcimimetic, is reported to decrease parathyroidism, as well as serum levels of phosphorus (P) and calcium (Ca) and therefore Ca x P product. Available evidence has shown that cinacalcet decreases the rate of parathyroidectomy and bone fracture in hemodialysis patients, but the death rate remains the same. Although, it is not yet available in Japan, cinacalcet is expected to be available as a possible drug for patients undergoing hemodialysis due to secondary hyperparathyroidism associated with refractory hyperphosphatemia and hypercalcemia. Except for the high cost, cinacalcet will be a welcome therapeutic option for end-stage renal disease and probably also for pre-end-stage renal disease patients. Dietary phosphate restriction and adequate hemodialysis, however, are still the main strategy for the control of hyperphosphatemia and secondary hyperparathyroidism.

show abstract

Guideline of selective parathyroid percutaneous etanol injection therapy for patients with advanced renal hyperparathyroidism

Cited by 2 publications

References 12 publications

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients

Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan

Contact Info

Product

Resources

About